In BRCA-deficient ovarian cancer, triple-negative breast cancer, and small cell lung cancer mouse models, Olaparib may activate the cGAS-STING pathway, upregulate CXCL10 and CCL5 expression, recruit CD8+ T cells to tumor tissue, and activate antitumor immune responses (133). This evidence concerns the gene CGAS and triple-negative breast carcinoma.